Inflammatory bowel disease surgery in the biologic therapy era

StrongS.A.

首页> 外文期刊>Current opinion in gastroenterology >Inflammatory bowel disease surgery in the biologic therapy era

【24h】

Inflammatory bowel disease surgery in the biologic therapy era

机译：生物治疗时代的炎症性肠病手术

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose of review: The relationship between surgery and biologic agents in the management of patients with inflammatory bowel disease continues to be a source of interest for both surgeons and clinicians. Recent findings: The role of biologic agents in patients with varying presentations of Crohn's disease or ulcerative colitis continues to evolve. However, the currently available biologic therapies are clearly not the panacea we have desired because they have only marginally decreased the frequency with which operative intervention is required and may have increased the risk for infectious postoperative complications in the nonelective setting. Compared to surgery, biologic agents are also significantly more costly and may not provide any greater gain in quality of life. SUMMARY: Future studies must focus on the use of surgery and emerging biologic agents as complementary therapies designed to safely control inflammatory disease while providing objective value.

机译：审查目的：炎症性肠病患者的手术和生物药物之间的关系仍然是外科医生和临床医生的兴趣来源。最近的发现：生物学剂在克罗恩病或溃疡性结肠炎的不同演示患者中的作用仍然发展。然而，目前可用的生物疗法显然不是我们所希望的灵丹妙药，因为它们仅略微降低了所需的操作干预的频率，并且可能增加了非选择性环境中传染性术后并发症的风险。与手术相比，生物制剂也明显更昂贵，并且可能无法提供生活质量的更多增益。摘要：未来的研究必须专注于使用手术和新兴生物剂作为互补疗法，旨在安全地控制炎症疾病，同时提供客观价值。

著录项

来源
《Current opinion in gastroenterology》 |2012年第4期|共5页
作者
StrongS.A.;
展开▼
作者单位

Department of Colorectal Surgery Cleveland Clinic Digestive Disease Institute Cleveland OH;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类消化系及腹部疾病;
关键词
biologic agents; cost; inflammatory bowel disease; operative complications; surgery;

机译：生物制剂;成本;炎症性肠病;手术并发症;手术;

相似文献

外文文献
中文文献
专利

1. The impact of preoperative biological therapy on complications after abdominal surgery for inflammatory bowel disease [J] . Gut: Journal of the British Society of Gastroenterology . 2013,第3期

机译：术前生物疗法对炎症性肠病腹部手术后并发症的影响
2. Preoperative biological therapy and short-term outcomes of abdominal surgery in patients with inflammatory bowel disease [J] . WatermanM., XuW., DinaniA., Gut: Journal of the British Society of Gastroenterology . 2013,第3期

机译：炎症性肠病患者的术前生物治疗和腹手术短期成果
3. The impact of preoperative biological therapy on complications after abdominal surgery for inflammatory bowel disease [J] . Gut: Journal of the British Society of Gastroenterology . 2013,第3期

机译：术前生物治疗对炎症性肠病腹部手术后并发症的影响
4. Natural anti-Inflammatory Compounds for the Management and Adjuvant Therapy of Inflammatory Bowel Disease (IBD) and its Drug Delivery System(DDS) for Targeted to Colon. [C] . Annual meeting exposition of the Controlled Release Society . 2009

机译：用于炎症性肠病（IBD）的管理和佐剂治疗的天然抗炎化合物及其药物递送系统（DDS）用于靶向结肠。
5. Oxidation Status as a Predictor of Disease Activity and Response to Therapy in Pediatric Patients with Inflammatory Bowel Disease [D] . Ajithkumar, Aravindh K. 2020

机译：氧化地位作为疾病活动的预测因素，对炎症性肠病儿科患者的疗法响应
6. Biological therapy and surgery rates in inflammatory bowel diseases – Data analysis of almost 1000 patients from a Hungarian tertiary IBD center [O] . Kata Szántó, Tibor Nyári, Anita Bálint, -1

机译：炎症性肠病的生物疗法和手术率–匈牙利第三级IBD中心近1000名患者的数据分析
7. Biological therapy and surgery rates in inflammatory bowel diseases – Data analysis of almost 1000 patients from a Hungarian tertiary IBD center [O] . Kata Szántó, Tibor Nyári, Anita Bálint, 2018

机译：炎症性肠病患者的生物疗法和手术率 - 近1000名匈牙利第三届IBD中心的数据分析
8. Medicare and Medicaid Coverage: Therapies and Supplies for Inflammatory Bowel Disease [R] . 2005

机译：医疗保险和医疗补助范围：炎症性肠病的治疗和用品

Inflammatory bowel disease surgery in the biologic therapy era

摘要

著录项

相似文献

相关主题

期刊订阅